Independent scientific review of antimicrobial efficacy data to support EPA submissions, label claims, and regulatory decision-making under FIFRA.
Were products tested properly and within acceptable time frames?
Are studies described in scientifically sound, EPA-acceptable study reports?
Is the protocol clearly delineated?
Does the study design support the intended label claims?
Which required efficacy studies may be missing?
Are additional studies needed to meet EPA expectations?
Can efficacy data be cited or bridged across related products?
Do dilutions, product types, or hardest-to-kill organisms support the label claims?
Does a formulation change trigger new efficacy data requirements?
Can “me-too” or similar formulations rely on existing data?
Do legacy studies meet current EPA antimicrobial guidelines?
Is a new study required to support existing claims?
Is it possible to avoid a new efficacy study?
Can a scientifically defensible waiver be supported?
Has an inert ingredient been flagged for potential antimicrobial activity?
Could inert components impact efficacy or regulatory status?
Are efficacy claims likely to be flagged during EPA screening or review?
Do claims align with available efficacy data?
Are all required efficacy documents included and complete?
Is the submission organized to minimize screening deficiencies?
Scientific responses to EPA questions, rejections, or data deficiencies
Support to move submissions forward after screening or review issues
Will the product be subject to an efficacy pDCI?
Which studies are required to comply?
Does marketed or printed labeling faithfully derive from the EPA-approved master label?
Regulatory and compliance review to identify FIFRA, jurisdictional, and enforcement issues before or after market entry.
Is the product a pesticide, pesticide device, treated article, cleaner, or not regulated under FIFRA?
Has a marketplace (e.g., Amazon) suspended or removed the product, requiring a letter from EPA?
Does the product qualify for the 25(b) exemption?
Are claims false or misleading under EPA policy?
Does the product qualify for the treated article exemption?
Do claims align with EPA treated article guidance?
Is appropriate data available to support device claims?
Are claims potentially false or misleading?
Identification and organization of key efficacy issues prior to engaging EPA
Preparation of supporting scientific and regulatory information
Is the product currently compliant with FIFRA and EPA antimicrobial expectations?
Is the product on hold due to false or misleading efficacy claims?
Efficacy-related scientific and regulatory analysis related to enforcement actions
Are website and marketing claims consistent with EPA-approved labeling?
Have online claims triggered compliance or enforcement concerns?
I provide reviews and assistance at multiple levels of detail and with flexible deliverable formats. Please reach out to receive documents (intake form, project scope, pricing, agreement and NDA).